RCM Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the 13 and 26 weeks ended July 2, 2022, compared with periods ended July 3, 2021. This differs from the request metadata’s “2021 Q2.” Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions unless otherwise noted.
Business context
RCM provides engineering, specialty healthcare staffing and services, and life sciences and information technology services. Most revenue is generated from time-and-materials work. The company reports Engineering, Specialty Health Care, and Information Technology segments; Life Sciences is discussed with Information Technology.
Financial performance
| Metric | 13 weeks ended July 2, 2022 | 13 weeks ended July 3, 2021 | 26 weeks ended July 2, 2022 | 26 weeks ended July 3, 2021 |
|---|---|---|---|---|
| Revenue | $74.3m | $48.9m | $156.3m | $93.5m |
| Gross profit / margin | $21.7m / 29.2% | $12.3m / 25.1% | $45.1m / 28.9% | $23.1m / 24.7% |
| Operating income / margin | $8.2m / 11.0% | $1.9m / 4.0% | $17.2m / 11.0% | $3.3m / 3.5% |
| Net income | $6.0m | $1.3m | $12.5m | $2.3m |
| Diluted earnings per share | $0.57 | $0.11 | $1.18 | $0.19 |
- Revenue increased 51.9% in the quarter and 67.2% for the half year. Specialty Health Care contributed the largest increase: $20.5m for the quarter and $51.5m for the half year. Half-year revenue was $95.6m in Specialty Health Care, $40.8m in Engineering, and $19.9m in Life Sciences and Information Technology.
- For the half year, cash provided by operating activities was $20.8m, versus $6.3m a year earlier. Investing activities used $0.5m, primarily for $0.4m of property and equipment; financing activities used $17.2m, including $14.2m of net line-of-credit repayments and $2.8m of share repurchases.
- Cash was $3.1m at July 2, 2022, compared with $0.2m at January 1, 2022. Accounts receivable, net, was $45.3m. The balance sheet reports current assets of $51.5m and current liabilities of $33.8m.
- Line-of-credit borrowings were zero at July 2, 2022, down from $14.2m at January 1, 2022. The $45.0m revolving facility expires August 8, 2023; borrowing availability was $43.1m, after $1.9m of outstanding letters of credit. The company reported covenant compliance. Finance lease liabilities were $0.7m and operating lease liabilities were $2.9m.
Material changes and management commentary
- Specialty Health Care growth reflected reopened school clients and strong demand for healthcare professionals. School-client revenue for the half year rose to $73.8m from $29.1m. Management cautioned that staffing professionals is difficult and that renewed school closures or a shift to endemic conditions could reduce demand.
- Engineering growth reflected aerospace outsourcing work, entry into the rocket industry, and increased industrial-processing customer spending. Segment margins improved, which management attributed to project execution, utilization management, and a focus on higher-margin work.
- Gross margin improved while SG&A rose in dollars but declined as a share of revenue: 17.7% for the half year versus 20.5%. Management said added hiring and investment supported increased demand and future growth.
- The company sold its Canadian Power Systems offices in July 2021. Those operations generated $4.4m of revenue in the first half of 2021 and are not part of the current-period business.
- No numerical full-year revenue or earnings guidance is provided. Management said it expects to meet liquidity needs for at least the next 12 months and expects to remain in compliance with credit covenants.
Risks, contingencies, and unusual items
- Management identifies economic cyclicality, customer concentration, credit and collection risk, competition and pricing pressure, and the ability to recruit and retain qualified personnel as key risks. Healthcare demand and school operations remain subject to pandemic-related uncertainty. Labor-rate increases, insurance claims, regulation, and foreign exchange movements could also affect results.
- The company had accrued $2.6m for asserted claims. Separately, an Industrial Processing client alleged that a partially designed system was not operating as intended. No liability was accrued because a loss was not determined to be probable; the company believes potential damages, if any, are contractually limited to $3.3m.
- Estimated remaining contingent consideration for the TKE acquisition was $0.6m, potentially payable in 2023 and 2024. Estimates depend on acquired-business performance.
- Management estimated a $0.5m–$1.0m cost to upgrade or replace its financial reporting and accounting system during fiscal 2022.
- The company repurchased 406,480 shares for $2.8m during the half year and reported $7.3m remaining under its repurchase authorization. Its at-the-market program, which permits up to $17.9m in sales, had not been used.
- Management reported effective disclosure controls. It also noted potential control execution challenges associated with virtual financial-close processes, but reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the correct period: the 10-Q is for the quarter ended July 2, 2022, not 2021 Q2.
- Reconcile current liabilities: the balance sheet reports $33.8m, while MD&A states $33.3m and says current assets exceeded current liabilities by $18.2m. The balance-sheet figures imply a different excess.
- Check the prior-year quarterly tax description: the statements report $0.5m of tax expense for the 13 weeks ended July 3, 2021, while MD&A describes a $0.5m tax benefit.
- Assess whether unusually rapid Specialty Health Care growth and improved margins can persist, given worker availability, customer concentration, and school/pandemic exposure.
- Monitor collections, the accrued and unbilled receivable balance, asserted claims and the Industrial Processing dispute, as well as planned accounting-system upgrade spending.